Introducing

CoreView™

CoreView™ is a Curated, Objective, Relevant Evidence Viewpoint of selected topics in musculoskeletal research, highlighting and graphically summarizing evidence in subject areas that are poorly understood for one of two reasons:
  1. There are numerous, high-quality studies but the data are examined so broadly that pockets of treatment efficacy are overlooked; or
  2. There is a growing body of evidence but the frequency with which clinical practice guidelines are produced creates significant latency in uptake among practitioners.
Confounding both cases is also bias (in methodology and in reporting) that tends to further hinder clear understanding of the state of the evidence.

The advantages of CoreView™

With CoreView™ topics, practitioners are able to:
  • Gain a high-level view based on dozens or hundreds of ACE™ reports;
  • Filter chart data across patient/product characteristics as well as outcomes;
  • Access underlying ACE™ reports by clicking on the bar charts.
CoreView™ content is continuously updated as new evidence is published, and we will add additional CoreView™ topics every few months.

The genesis of CoreView™: OE's ACE™ Report

Our first product, the Advanced Clinical Evidence (ACE™) Report, was designed to be a 700-word summary that would help busy practitioners identify important findings and quickly assess whether a study (randomized clinical trial, meta-analysis or systematic review) was worth examining in greater detail. We did this by including in each report a critical appraisal of the risk of bias and the methodology employed in the original publication.

As our library of ACE™ Reports grew into thousands, we realized it was sometimes difficult for readers to reconcile one study’s recommendations with those of several others, despite similarities in the quality of evidence. We needed to elevate the view to enable our members to see the whole picture. Better yet, if we could provide a means for our members to actually choose which viewpoint they were looking through, we could actually help speed up the rate with which good research would be disseminated.